• serum
  • The authors concluded that serum levels of CA125 before and after TAVI independently predict death and MACE. (acc.org)
  • known
  • Low malignant potential (LMP) tumors, also known as borderline tumors, do not cause an increase in CA125 levels and are not identifiable with an ultrasound. (wikipedia.org)
  • treatment
  • If CA-125 levels fall during therapy, this generally indicates that the cancer is responding to treatment. (labtestsonline.org)
  • It appears that baseline CA125 values might be a useful tool for the determination of the optimal time point for TAVI, and patients with elevated levels of CA125 may require a more aggressive treatment before the procedure. (acc.org)
  • Prognosis relates to both the initial and post-treatment CA-125 values. (wikipedia.org)
  • values
  • Second, patients with elevated baseline CA125 values showed an independent increase of risk for all-cause death or MACE after TAVI. (acc.org)
  • Type
  • Explicitly, serial CA125 measurements after TAVI were significant predictors of both outcomes, even when modeled simultaneously with time-varying N-terminal pro-B-type natriuretic peptide, logistic EuroSCORE, baseline NYHA functional class III/IV, and device success. (acc.org)
  • strong
  • This study reported that CA125 was a strong predictor of death or MACE in a longitudinal setting after TAVI. (acc.org)
  • Often
  • 125 and 126 form a Ruth-Aaron pair under the second definition in which repeated prime factors are counted as often as they occur. (wikipedia.org)